Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Nancy L. Bartlett, MD, Betsy R. LaPlant, MS, Jing Qi, MD PhD, Stephen M. Ansell, MD PhD, John G. Kuruvilla, MD, Craig B. Reeder, MD, Lim S. Thye, MD, Daniel M. Anderson, MD MPH, Charles Erlichman, MD, Barry A. Siegel, MD

Blood (2014) 124 (21): 800.

https://doi.org/10.1182/blood.V124.21.800.800

Published: 2014

Journal Articles

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Wei Ding, MD, PhD, Tait D Shanafelt, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Betsy R. LaPlant, Timothy G. Call, MD, Curtis A Hanson, MD, Charles Erlichman, MD, Thomas M. Habermann, MD, Craig Reeder, MD, Daniel Nikcevich, Deborah Bowen, CNP, Michael J. Conte, PA-C, Justin Boysen, Charla Secreto, Connie Lesnick, M.Sc, Renee C. Tschumper, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2013) 122 (21): 2882.

https://doi.org/10.1182/blood.V122.21.2882.2882

Published: 2013

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

Wei Ding, MD, PhD, Tait D. Shanafelt, MD, Connie Lesnick, M.Sc, Traci Sassoon, Charla Secreto, Charles Erlichman, MD, Jose Leis, MD, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Shaji K. Kumar, MD, Neil E. Kay, MD

Blood (2012) 120 (21): 3928.

https://doi.org/10.1182/blood.V120.21.3928.3928

Published: 2012

Journal Articles

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

Stephen M Ansell, MD, PhD, Hui Tang, PhD, Grzegorz S. Nowakowski, MD, Daniel Nikcevich, MD, PhD, Garth D Nelson, Charles Erlichman, MD, Thomas E Witzig, MD, North Central Cancer Treatment Group

Blood (2010) 116 (21): 2862.

https://doi.org/10.1182/blood.V116.21.2862.2862

Published: 2010

Journal Articles

A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma.

Shaji Kumar, MD, Patrick J. Flynn, MD, Wee Joo J Chng, MD, Kenny Ieng Kit Lei, MD, FRCP, Jacob Allred, Kristina Laumann, Kevin Webster, Morie A Gertz, MD, Angela Dispenzieri, MD, Philip R. Greipp, MD, Suzanne R. Hayman, MD, Steven R. Zeldenrust, M.D., Ph.D., Charles Erlichman, MD, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD

Blood (2009) 114 (22): 4954.

https://doi.org/10.1182/blood.V114.22.4954.4954

Published: 2009

Journal Articles

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Cristina Joao, MD, Luis F. Porrata, MD, Thomas Witzig, MD, Paul Kurtin, Ivana Micallef, MD, Svetomir N. Markovic, MD, PhD, Charles Erlichman, MD, Anne Novak, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 1495.

https://doi.org/10.1182/blood.V106.11.1495.1495

Published: 2005

Journal Articles

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

Morie Abraham Gertz, MD, Susan M. Geyer, PhD, Brad S. Kahl, MD, Ashraf Badros, MD, Craig Reeder, MD, Charles Erlichman, MD

Blood (2004) 104 (11): 2407.

https://doi.org/10.1182/blood.V104.11.2407.2407

Published: 2004

Journal Articles

The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.

Angela Dispenzieri, MD, Keith C. Bible, MD, PhD, Martha Q. Lacy, MD, Tom R. Fitch, MD, Susan M. Geyer, PhD, Robert Fenton, MD, Rafael Fonseca, MD, Crescent R. Getman, Steven C. Ziesmer, Charles Erlichman, MD, Morie A. Gertz, MD

Blood (2004) 104 (11): 3461.

https://doi.org/10.1182/blood.V104.11.3461.3461

Published: 2004

Journal Articles

A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia.

Ruben A. Mesa, MD, John K. Camoriano, MD, Susan M. Geyer, PhD, Scott H. Kaufmann, MD, PhD, Candido E. Rivera, MD, Charles Erlichman, MD, Ayalew Tefferi, MD

Blood (2004) 104 (11): 1509.

https://doi.org/10.1182/blood.V104.11.1509.1509

Published: 2004

NARROW

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma.

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.

A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only